Achaogen Inc (AKAO) Given Consensus Rating of “Buy” by Brokerages
Achaogen Inc (NASDAQ:AKAO) has been assigned a consensus rating of “Buy” from the fourteen analysts that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $25.48.
Several analysts have issued reports on the company. Mizuho restated a “buy” rating and set a $28.00 price objective on shares of Achaogen in a report on Thursday, September 28th. Guggenheim restated a “buy” rating and set a $14.00 price objective on shares of Achaogen in a report on Wednesday. ValuEngine upgraded Achaogen from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. SunTrust Banks cut their price objective on Achaogen to $27.00 and set a “buy” rating on the stock in a report on Wednesday, January 3rd. Finally, Zacks Investment Research downgraded Achaogen from a “hold” rating to a “sell” rating in a report on Tuesday.
In other news, major shareholder Robert W. Duggan acquired 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were purchased at an average price of $10.89 per share, for a total transaction of $163,350.00. Following the completion of the acquisition, the insider now owns 5,617,752 shares of the company’s stock, valued at approximately $61,177,319.28. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Robert W. Duggan acquired 95,012 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The stock was purchased at an average price of $11.13 per share, for a total transaction of $1,057,483.56. Following the acquisition, the insider now directly owns 5,602,752 shares of the company’s stock, valued at approximately $62,358,629.76. The disclosure for this purchase can be found here. Insiders bought a total of 160,012 shares of company stock worth $1,796,334 in the last quarter. 8.36% of the stock is owned by corporate insiders.
Shares of Achaogen (AKAO) opened at $12.42 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 6.99 and a current ratio of 6.99. The stock has a market capitalization of $526.53, a PE ratio of -3.70 and a beta of 1.35. Achaogen has a twelve month low of $10.24 and a twelve month high of $27.79.
Achaogen (NASDAQ:AKAO) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.13). The company had revenue of $0.58 million for the quarter, compared to analyst estimates of $2.09 million. Achaogen had a negative return on equity of 80.44% and a negative net margin of 593.61%. Achaogen’s quarterly revenue was down 96.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.41) EPS. equities analysts expect that Achaogen will post -3.06 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Achaogen Inc (AKAO) Given Consensus Rating of “Buy” by Brokerages” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/12/achaogen-inc-akao-given-consensus-rating-of-buy-by-brokerages.html.
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.